Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celldex Therapeutics

20.66
-0.0500-0.24%
Post-market: 20.660.00000.00%16:05 EDT
Volume:598.56K
Turnover:12.48M
Market Cap:1.37B
PE:-8.43
High:21.23
Open:20.94
Low:20.64
Close:20.71
Loading ...

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
28 Feb

Celldex Therapeutics Inc : UBS Initiates Coverage With Buy Rating and Target Price $44

THOMSON REUTERS
·
13 Feb

Celldex Therapeutics And 2 Other Undervalued Small Caps With Insider Action In US

Simply Wall St.
·
31 Jan

Celldex Therapeutics Price Target Maintained With a $67.00/Share by Cantor Fitzgerald

Dow Jones
·
29 Jan

Cantor Fitzgerald Sticks to Their Buy Rating for Celldex (CLDX)

TIPRANKS
·
29 Jan

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Simply Wall St.
·
29 Jan

BUZZ-Leerink Partners raises PT on Blueprint Medicines

Reuters
·
15 Jan

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Celldex (CLDX) and Centessa Pharmaceuticals (CNTA)

TIPRANKS
·
13 Jan

Celldex Therapeutics Price Target Maintained With a $67.00/Share by Cantor Fitzgerald

Dow Jones
·
02 Jan

Analysts Are Bullish on These Healthcare Stocks: Jasper Therapeutics (JSPR), Celldex (CLDX)

TIPRANKS
·
02 Jan

January 2025's Undervalued Small Caps With Insider Action On US Markets

Simply Wall St.
·
02 Jan

Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Dec 2024

Celldex initates Phase 2 study of barzolvolimab in AD

TIPRANKS
·
19 Dec 2024

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

THOMSON REUTERS
·
19 Dec 2024

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

GlobeNewswire
·
19 Dec 2024

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

Zacks
·
13 Dec 2024

Insider Spends US$308k Buying More Shares In Celldex Therapeutics

Simply Wall St.
·
21 Nov 2024

Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment

MT Newswires Live
·
20 Nov 2024

BRIEF-Celldex Announces First Patient Dosed In Phase 1 Healthy Volunteer Study Of CDX-622

Reuters
·
20 Nov 2024

Celldex Therapeutics Inc - Subcutaneous Formulation to Be Added to Study in 2025

THOMSON REUTERS
·
20 Nov 2024